|
|
| The IBCG mission, in collaboration with UroToday, focuses on two key goals: improving bladder cancer patient outcomes through data-driven, evidence-based treatments, and creating practical educational tools to support the global urological community in enhancing patient care worldwide. |
|
|
| QUARTERLY NEWSLETTER |
December 2024 | Volume 3 |
|
|
|
 |
Conference Summaries |
|
| CONFERENCE SUMMARY |
| IBCG Retreat 2024 |
| Kelly Bree, MD, and Niyati Lobo, MD |
 |
|
 |
|
| The annual International Bladder Cancer Group (IBCG) Retreat was held in Houston, Texas, from August 23-24, 2024. Co-chaired by Drs. Shilpa Gupta, Roger Li, and Patrick Hensley, the event brought together over 90 international bladder cancer clinicians, scientists, and patient advocates, with IBCG representation spanning five continents. The aim of the retreat was to develop consensus statements on two disease processes. |
|
|
|
|
|
|
|
|
Conference Highlights |
|
| Highlights from ESMO’24 Presidential Symposium: Bladder Cancer in the Forefront |
 |
|
| Petros Grivas, MD |
|
In Barcelona this past September, we witnessed another major milestone in the rapid development of bladder cancer therapeutics. The practice changing data of the phase III NIAGARA trial showed that perioperative (neoadjuvant and adjuvant) durvalumab (anti-PD-L1) plus neoadjuvant gemcitabine/cisplatin improved both event-free survival (EFS) and overall survival (OS) vs chemotherapy alone, without jeopardizing the ability of patients to pursue curative-intent radical cystectomy.
|
|
|
|
|
|
| IBCN 2024: Highlights |
 |
|
| Amanda Myers, MD |
|
The IBCN 2024 occurred in Bern, Switzerland, from September 19th to September 21st, 2024. The event featured a keynote lecture on Friday morning by Niko Beerenwinkel, Professor of Computational Biology ETH Zurich, on “Inferring Tumor Evolution from Single-Cell Data.” Dr. Beerenwinkel discussed the evolutionary process of cancer, which can be visualized through tumor phylogeny and cell lineage trees. Phylogenetic tree reconstruction can be performed by using single-cell sequencing from a tumor biopsy.
|
|
|
|
|
|
|
|
| Promoting BCAN’s 2025 Walks to End Bladder Cancer: Join the Fight Against Bladder Cancer |
|
|
Bladder cancer is one of the most common cancers in the United States, impacting approximately 83,000 Americans each year. It is a disease that shocks not only the individuals diagnosed but also their families, caregivers, and communities. For healthcare providers, medical researchers, and doctors, bladder cancer deserves significant attention due to its prevalence and the urgent need for better treatments and outcomes. One of the most impactful ways you can contribute to the fight against this disease is by supporting the Bladder Cancer Advocacy Network’s (BCAN) 2025 Walks to End Bladder Cancer.
|
|
|
|
|
|
| Systemic Treatment in Bladder Cancer State of Art in 2024 and Challenges in Morocco |
| Karima Oualla, MD, MSc, Mehdi Alem, MD, and Nawfel Mellas, MD |
|
Bladder cancer treatment has evolved from traditional surgery and chemotherapy to include immunotherapy, targeted therapies, and antibody drug conjugates. These therapeutic innovations, along with advances in surgical techniques and multimodal approaches, continue to reshape clinical practice and improve outcomes for bladder cancer patients. However, the high cost of these treatments poses a significant challenge in low-income countries such as Morocco.
|
|
|
|
|
|
|
|
|
